David J. Brailer was appointed Director of Teva Pharmaceutical Industries Ltd, effective November 3, 2026. As of November 6, 2026, Teva Pharmaceutical Industries Ltd has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on October 29, 2026, naming 1 appointment (Form 8-K, October 29, 2026).
TEVA PHARMACEUTICAL INDUSTRIES LTD named a new Director on Oct 29. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Teva Pharmaceutical Industries Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Teva Pharmaceutical Industries Ltd reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-29. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Teva Pharmaceutical Industries Ltd files it.
Also on the record for Teva Pharmaceutical Industries Ltd
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 2, 2026 | Stake report, Schedule 13G/A, by Harel Insurance Investments & Financial Services Ltd. | 6% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Migdal Insurance & Financial Holdings Ltd | 5.37% of the class | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G/A, by Harel Insurance Investments & Financial Services Ltd | 6.3% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 2.1% of the class | 5%+ stakes | Source |
| October 6, 2025 | Stake report, Schedule 13G, by Harel Insurance Investments & Financial Services Ltd | 5.1% of the class | 5%+ stakes | Source |
| August 6, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 5.1% of the class | 5%+ stakes | Source |
| July 22, 2025 | Stake report, Schedule 13G, by Phoenix Financial Ltd. | 5% of the class | 5%+ stakes | Source |
| July 17, 2025 | Stake report, Schedule 13G, by Menora Mivtachim Holdings Ltd | 5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Teva Pharmaceutical Industries Ltd now and the warning signs.
Free to see. No signup.
Keep reading
More on Teva Pharmaceutical Industries Ltd and the records around it.
Teva Pharmaceutical Industries Ltd elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Menora Mivtachim Holdings Ltd also filed stake reports on 7 other companies: CAMTEK LTD (Oct 2026), Ellomay Capital Ltd (Aug 2026), FORMULA SYSTEMS (1985) LTD (Aug 2026)
- Migdal Insurance & Financial Holdings Ltd also filed stake reports on 10 other companies: Camtek Ltd (Oct 2026), Enlight Renewable Energy Ltd (Jul 2026), Ormat Technologies, Inc. (Jul 2026)
- Harel Insurance Investments & Financial Services Ltd also filed stake reports on 16 other companies: Perion Network Ltd (Nov 2026), Tower Semiconductor Ltd (Nov 2026), ELBIT SYSTEMS LTD (Oct 2026)
Watch Teva Pharmaceutical Industries Ltd
Get an email when Teva Pharmaceutical Industries Ltd files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Teva Pharmaceutical Industries Ltd?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Teva Pharmaceutical Industries Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Teva Pharmaceutical Industries Ltd covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-29 | In | Director | 2026-11-03 | 8-K, 2026-10-29 |
Who leads Teva Pharmaceutical Industries Ltd, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: David J. Brailer, appointed, effective 2026-11-03 (filed 2026-10-29).
New leaders reset buying decisions — get the Full Report on Teva Pharmaceutical Industries Ltd: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Teva Pharmaceutical Industries Ltd, with the record behind each one.
Find candidates like Director at Teva Pharmaceutical Industries LtdEvery change, in the filing's words
Appointed: David J. Brailer, Director, effective 2026-11-03
On October 27, 2026, at a meeting of the Board of Directors (the "Board") of Teva Pharmaceutical Industries Ltd. ("Teva" or the "Company"), the Board elected Dr. David J. Brailer to serve as a member of the Board, effective November 3, 2026, until Teva's 2027 annual meeting of shareholders.
- The Board determined that Dr. Brailer qualifies as an independent director under the listing rules of the New York Stock Exchange, and he is expected to serve on the Human Resources and Compensation and Compliance Committees of the Board.
- Dr. Brailer has served as Chairman and Chief Executive Officer of medem.ai, a health-tech company, since 2024, as Founder and Executive Chairman of Health Evolution since 2010, and as Founder and Managing Partner of Health Evolution Partners since 2007.
- From 2022 to 2026, Dr. Brailer served as Chief Health Officer of The Cigna Group and, from 2024 to 2026, also as its Chief Transformation Officer.
- Since 2021, he has served as Vice Chairman of the Duke Margolis Health Policy Institute.
- Dr. Brailer previously served on the boards of directors of Prolacta Bioscience, Inc. from 2012 to 2023, and Walgreens Boots Alliance, Inc., from 2012 to 2021.
- Dr. Brailer received a Ph.D. in Management Science and Applied Economics from The Wharton School of the University of Pennsylvania, and an M.D., with honors, and a B.S., cum laude, from West Virginia University.
- Dr. Brailer has declared in writing that he possesses the requisite skills and expertise, as well as sufficient time, to perform his duties as a director of Teva, as required pursuant to the Israeli Companies Law, 5759-1999.
Tools for this story
Each opens in a new tab, filled in for Teva Pharmaceutical Industries Ltd. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.